Raksul Inc. (FRA:49R)
Germany · Delayed Price · Currency is EUR 7.25
+0.10 (1.40%)
Last updated: Jul 31, 2025
Intra-Cellular Therapies Income Statement
Financials in millions JPY. Fiscal year is August - July.
Millions JPY. Fiscal year is Aug - Jul.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '25 Apr 30, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 | Jul '20 Jul 31, 2020 | 2018 - 2020 |
| 59,314 | 51,121 | 41,018 | 33,980 | 30,261 | 21,495 | Upgrade | |
Revenue Growth (YoY) | 22.41% | 24.63% | 20.71% | 12.29% | 40.78% | 25.20% | Upgrade |
Cost of Revenue | 38,777 | 33,929 | 28,722 | 24,176 | 23,109 | 16,566 | Upgrade |
Gross Profit | 20,537 | 17,192 | 12,296 | 9,804 | 7,152 | 4,928 | Upgrade |
Selling, General & Admin | 17,185 | 14,668 | 10,529 | 9,344 | 6,931 | 5,172 | Upgrade |
Operating Expenses | 17,185 | 14,668 | 10,529 | 9,340 | 6,931 | 5,172 | Upgrade |
Operating Income | 3,352 | 2,524 | 1,767 | 464 | 220.56 | -244.28 | Upgrade |
Interest Expense | -110 | -65 | -54 | -34 | -32.99 | -88.61 | Upgrade |
Interest & Investment Income | 16 | 13 | 11 | 11 | 10.17 | 7.67 | Upgrade |
Earnings From Equity Investments | -314 | -382 | -513 | -532 | - | - | Upgrade |
Currency Exchange Gain (Loss) | -18 | -3 | 6 | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | -54 | -45 | -49 | -77 | 1 | -39.76 | Upgrade |
EBT Excluding Unusual Items | 2,872 | 2,042 | 1,168 | -168 | 198.74 | -364.98 | Upgrade |
Gain (Loss) on Sale of Investments | 1,407 | 1,407 | 1,339 | 708 | -20.97 | -3.45 | Upgrade |
Gain (Loss) on Sale of Assets | -340 | - | - | - | - | - | Upgrade |
Asset Writedown | - | - | -11 | -2 | -7.96 | -20.29 | Upgrade |
Legal Settlements | -30 | -30 | - | -39 | - | - | Upgrade |
Other Unusual Items | 27 | 12 | 6 | -2 | -64.47 | - | Upgrade |
Pretax Income | 3,936 | 3,431 | 2,502 | 497 | 105.34 | -388.72 | Upgrade |
Income Tax Expense | 1,586 | 1,389 | 1,173 | -524 | -54.67 | 105.41 | Upgrade |
Earnings From Continuing Operations | 2,350 | 2,042 | 1,329 | 1,021 | 160.01 | -494.14 | Upgrade |
Minority Interest in Earnings | - | 76 | - | - | - | - | Upgrade |
Net Income | 2,350 | 2,118 | 1,329 | 1,021 | 160.01 | -494.14 | Upgrade |
Net Income to Common | 2,350 | 2,118 | 1,329 | 1,021 | 160.01 | -494.14 | Upgrade |
Net Income Growth | 17.03% | 59.37% | 30.17% | 538.11% | - | - | Upgrade |
Shares Outstanding (Basic) | 58 | 58 | 58 | 58 | 57 | 56 | Upgrade |
Shares Outstanding (Diluted) | 58 | 61 | 61 | 62 | 57 | 56 | Upgrade |
Shares Change (YoY) | -5.57% | -0.26% | -0.50% | 8.15% | 1.70% | -4.20% | Upgrade |
EPS (Basic) | 40.44 | 36.32 | 22.85 | 17.68 | 2.81 | -8.82 | Upgrade |
EPS (Diluted) | 39.23 | 34.53 | 21.57 | 16.47 | 2.81 | -8.82 | Upgrade |
EPS Growth | 20.06% | 60.05% | 30.99% | 486.56% | - | - | Upgrade |
Free Cash Flow | - | 2,318 | 2,894 | 834 | 1,527 | -153.17 | Upgrade |
Free Cash Flow Per Share | - | 37.90 | 47.19 | 13.53 | 26.80 | -2.73 | Upgrade |
Dividend Per Share | 1.700 | 1.700 | - | - | - | - | Upgrade |
Gross Margin | - | 33.63% | 29.98% | 28.85% | 23.63% | 22.93% | Upgrade |
Operating Margin | 5.65% | 4.94% | 4.31% | 1.37% | 0.73% | -1.14% | Upgrade |
Profit Margin | 3.96% | 4.14% | 3.24% | 3.00% | 0.53% | -2.30% | Upgrade |
Free Cash Flow Margin | - | 4.53% | 7.05% | 2.45% | 5.05% | -0.71% | Upgrade |
EBITDA | 5,518 | 4,073 | 2,493 | 938 | 418.02 | -73.29 | Upgrade |
EBITDA Margin | - | 7.97% | 6.08% | 2.76% | 1.38% | -0.34% | Upgrade |
D&A For EBITDA | 2,166 | 1,549 | 726 | 474 | 197.47 | 170.99 | Upgrade |
EBIT | 3,352 | 2,524 | 1,767 | 464 | 220.56 | -244.28 | Upgrade |
EBIT Margin | - | 4.94% | 4.31% | 1.36% | 0.73% | -1.14% | Upgrade |
Effective Tax Rate | - | 40.48% | 46.88% | - | - | - | Upgrade |
Advertising Expenses | - | 3,813 | 3,120 | 2,557 | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.